Jaguar Health Inc
NASDAQ:JAGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jolywood Suzhou Sunwatt Co Ltd
SZSE:300393
|
CN |
Jaguar Health Inc
Cash
Jaguar Health Inc
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jaguar Health Inc
NASDAQ:JAGX
|
Cash
$968k
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash
$3.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jaguar Health Inc
Glance View
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
See Also
What is Jaguar Health Inc's Cash?
Cash
968k
USD
Based on the financial report for Dec 31, 2025, Jaguar Health Inc's Cash amounts to 968k USD.
What is Jaguar Health Inc's Cash growth rate?
Cash CAGR 5Y
-35%
Over the last year, the Cash growth was -88%. The average annual Cash growth rates for Jaguar Health Inc have been -44% over the past three years , -35% over the past five years .
